publication date: Feb. 7, 2014


In Brief
Selig Named President of NCCR Board

THE NATIONAL COALITION FOR CANCER RESEARCH elected members to its board of directors. Wendy Selig was elected president.

Selig is president and CEO of the Melanoma Research Alliance. Previously, she spent nearly a decade in leadership positions at the American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network. Most recently, she served as ACS CAN’s vice president of external affairs & strategic alliances.

In addition, the following were elected to the board of directors: Robert Clark, director of government affairs at St. Jude Children’s Research Hospital; Anne Levine, vice president of external affairs at Dana-Farber Cancer Institute; David Pugach, director of federal relations at the American Cancer Society Cancer Action Network; and Jon Retzlaff, managing director of science policy and government affairs at the American Association for Cancer Research.

was awarded a $900,000 grant from the Ovarian Cancer Research Fund to test new combinations of targeted drugs against the disease.

Ursula Matulonis, the director of the Gynecological Cancer Treatment Center in the Susan F. Smith Center for Women’s Cancers at Dana-Farber, is the principal investigator of the project. This grant helped mark the OCRF’s 20th anniversary, for which the fund awarded $6.9 million in gynecologic cancer research and program grants.

Researchers will explore a number of strategies that combine drugs that simultaneously target several abnormal biologic pathways in ovarian cancer cells. In one project, researchers will test the effectiveness of a PARP inhibitor and another targeted therapy in blocking the abnormal PI3-kinase signaling pathway in ovarian … Continue reading 40-06 In Brief

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.